Huperzine A

Drug Profile

Huperzine A

Alternative Names: HupA oral; Huperzine A oral; Qian-ceng-ta

Latest Information Update: 11 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chinese Academy of Sciences; Mayo Clinic
  • Developer Chinese Academy of Sciences; Neuro-Hitech
  • Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 10 Feb 2011 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
  • 05 Feb 2008 Interim efficacy data from the double-blind part of a phase II trial in patients with mild-to-moderate Alzheimer's disease released by Neuro-Hitech
  • 15 Dec 2007 Neuro-Hitech completes the double-blind portion of a phase II trial in Alzheimer's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top